IgG-like bispecific T-cell–redirecting antibody that binds FcRH5 on myeloma/plasma cells and CD3 on T cells, inducing T cell–mediated cytotoxicity.
IgG-like bispecific antibody that binds FCRH5 on myeloma/plasma cells and CD3 on T cells, crosslinking T cells to tumor cells to activate TCR/CD3 signaling and induce T cell–mediated cytotoxic lysis of FCRH5-expressing cells.
NO
INDIRECT
Cevostamab bridges CD3 on T cells to FCRH5 on myeloma cells, activating T cells to kill FCRH5+ tumor cells via perforin/granzyme-mediated lysis; CD3+ cells are not the targets killed.
IgG-like bispecific T-cell engager targeting BCMA on myeloma cells and CD3, triggering T-cell activation and lysis of tumor cells.
IgG-like bispecific antibody that binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking T cells with tumor cells to activate cytotoxic T-lymphocyte responses and induce lysis of BCMA-expressing myeloma cells.
YES
DIRECT
Bispecific binding to CD3 and BCMA cross-links T cells with BCMA+ cells, activating CTLs to form an immune synapse and kill targets via perforin/granzyme-mediated lysis/apoptosis.
Rabbit polyclonal anti-thymocyte globulin that depletes T cells to prevent rejection and GVHD.
Rabbit polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, producing immunosuppression to prevent rejection and GVHD.
YES
DIRECT
Polyclonal anti-thymocyte IgG binds CD7 on T cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC (and apoptosis), depleting CD7+ cells.
IgG-like bispecific T-cell engager targeting BCMA on myeloma cells and CD3, triggering T-cell activation and lysis of tumor cells.
IgG-like bispecific antibody that binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking T cells with tumor cells to activate cytotoxic T-lymphocyte responses and induce lysis of BCMA-expressing myeloma cells.
NO
INDIRECT
Elranatamab binds CD3 on T cells to activate and tether them to BCMA-expressing tumor cells; the activated T cells kill BCMA+ myeloma cells via cytolysis (perforin/granzyme), not CD3e+ T cells.
A bispecific T-cell engager (BiTE) antibody construct that binds CD19 on B cells and CD3 on T cells to redirect cytotoxic T cells to eliminate CD19+ B cells, reducing pathogenic B cells/plasmablasts and autoantibody production.
Blinatumomab is a BiTE antibody that simultaneously binds CD19 on B cells and CD3 on T cells, bringing T cells into contact with CD19+ B cells to activate cytotoxic T-cell killing (perforin/granzyme), leading to rapid depletion of pathogenic B cells/plasmablasts and reduced autoantibody production.
YES
DIRECT
Blinatumomab bridges CD3+ T cells to CD19+ cells, inducing immune synapse formation and T-cell cytotoxicity via perforin/granzyme-mediated apoptosis of CD19-expressing cells.